Enzymatic DNA Synthesis Market (2025 - 2033) Size, Share & Trends Analysis Report By Services (Oligonucleotide Synthesis, Gene Synthesis), By Application (Synthetic Biology, Vaccine Development), By End Use, By Region, And Segment Forecasts

Enzymatic DNA Synthesis Market Summary

The global enzymatic DNA synthesis market size was estimated at USD 292.9 million in 2024, is projected to reach USD 2,444.7 million by 2033, expanding at a CAGR of 26.65% from 2025 to 2033. Owing to advancements in technology, rising demand for precision medicine, increased research in synthetic biology, and greater funding for genetic research and biotechnology are anticipated to drive the growth of the enzymatic DNA synthesis market.

Automation Breakthrough Expands Scope of Enzymatic DNA Applications

Moreover, the expanding biopharmaceutical sector, with its focus on innovative drug development and genetic research, is further propelling the enzymatic DNA synthesis market over the forecast period. Enzymatic DNA synthesis continues to push the boundaries of molecular manufacturing, with recent breakthroughs demonstrating its potential beyond traditional biotechnology. A pioneering development featured in PNAS introduces the DNA-DISK platform, which integrates enzymatic single-nucleotide DNA synthesis and sequencing with digital microfluidics. This end-to-end, fully automated system encodes digital data into DNA strands using terminal deoxynucleotidyl transferase (TdT), offering a streamlined and scalable alternative to conventional synthesis and sequencing workflows. By eliminating harsh chemicals and enabling synthesis in aqueous environments, this platform aligns with the global shift toward safer, faster, and more sustainable production methods.

The innovation lies in its ability to automate the entire DNA data storage cycle-from writing to reading-within a compact and digitally controlled setup. The system's enzymatic precision allows for single-base additions, essential for encoding data accurately. This development reinforces enzymatic DNA synthesis as a flexible tool that can support decentralized synthesis models, especially in domains that require high-throughput and precision, such as bioinformatics and digital archiving. Companies in the sector, including DNA Script, Molecular Assemblies, and Ansa Biotechnologies, are already pursuing similar technological directions to meet demand for advanced, application-specific synthesis platforms.

This advancement reflects the evolving scope and commercial potential of enzymatic synthesis technologies. As demand grows for miniaturized, sustainable, and automated systems capable of operating beyond genomic applications, innovations such as DNA-DISK signal a significant market opportunity. DNA-based data storage-valued for its density, longevity, and eco-efficiency-is gaining traction as a frontier technology. The ability to synthesize and process DNA sequences autonomously opens doors to new collaborations and market expansion, positioning enzymatic synthesis as a critical enabler of next-generation molecular solutions across synthetic biology, data science, and decentralized biomanufacturing.

Scalable DNA Innovation Reshaping the Future of Synthetic Biology

Enzymatic DNA synthesis (EDS) is rapidly emerging as a transformative alternative to traditional chemical methods, addressing long-standing limitations in length, fidelity, and environmental sustainability. While phosphoramidite chemistry has dominated DNA synthesis for decades, it struggles to efficiently produce sequences beyond 300 bases due to cumulative cycle inefficiencies and high error rates. In contrast, EDS uses terminal deoxynucleotidyl transferase (TdT) to add nucleotides under mild, aqueous conditions, enabling high-purity synthesis of longer DNA fragments. This leap in technical capability is crucial for supporting advanced applications in genomics, gene editing, synthetic biology, and mRNA-based drug development.

From a commercial standpoint, the shift toward EDS is unlocking new growth avenues across the life sciences sector. The ability to produce long, accurate, and sequence-diverse DNA constructs quickly and sustainably offers a competitive edge in high-throughput R&D and decentralized biomanufacturing. Companies pioneering this shift are gaining strategic traction by offering benchtop instruments, on-demand synthesis services, and early-access programs tailored for use in therapeutics, vaccine development, and next-generation bioengineering. As industries prioritize faster iteration cycles, reduced reliance on outsourcing, and greener technologies, enzymatic DNA synthesis is redefining the competitive landscape, positioning itself as a cornerstone of the evolving synthetic biology ecosystem.

Market Concentration & Characteristics

The degree of innovation in the enzymatic DNA synthesis industry is moderate. While there are ongoing advancements in enzyme technologies and synthesis methods that have enhanced efficiency, accuracy, and scalability, the overall rate of innovation is steady rather than explosive.

The market is also characterized by the moderate level of merger and acquisition activities undertaken by several industry players. These strategic is expected to enable companies to access new markets, acquire innovative technologies, and achieve economies of scale, further driving competition and partnership within the enzymatic DNA synthesis industry.

Regulatory requirements governing enzymatic DNA synthesis services present significant challenges for market players. These regulations often involve stringent standards for accuracy, safety, and quality, which can increase the complexity and cost of operations. Thus, the regulatory landscape is anticipated to slow down market entry and limit the flexibility of businesses in this competitive field.

The enzymatic DNA synthesis industry is experiencing exponential growth and product expansion, attributed to advancements in technology, increasing demand for synthetic biology applications, and the rising need for more efficient and accurate DNA synthesis methods.

The enzymatic DNA synthesis industry is experiencing exponential regional expansion, attributed to the growing global demand for synthetic biology and genomics research, coupled with increased investments in biotechnology across various regions. Thus, the industry is rapidly extending its presence into emerging markets, developing new opportunities and driving growth on a global scale.

Type Insights

The oligonucleotide synthesis segment held the largest market share in 2024 due to its wide range of applications, including genetic research, diagnostics, and therapeutic development. Moreover, the increasing demand for precise and customized oligonucleotides in both research & clinical settings, along with advancements in synthesis technologies that enhance efficiency and reduced costs, is further anticipated to contribute to the growth of the segment for the enzymatic DNA synthesis market over the forecast period.

The gene synthesis segment is expected to grow at the fastest CAGR over the forecast period. This is attributed to the increasing applications of gene synthesis in various fields such as drug discovery, synthetic biology, and personalized medicine. In addition, the growing focus on genetic research and the demand for customized genetic solutions are further propelling the expansion of this segment.

Application Insights

The synthetic biology segment dominated the market in terms of revenue in 2024 with a market share of 36.55% and is expected to grow at fastest CAGR over the forecast period. This is attributed to the rapid advancements and increasing applications of synthetic biology in various fields, including drug development, agriculture, and environmental solutions. Moreover, the ongoing innovations, expanding research applications, and increasing investments in synthetic biology technologies is further anticipated to impel the growth of the segment over the forecast period.

The vaccine development segment is anticipated to grow at a significant CAGR of 26.99% over the forecast period. Synthetic DNA have made way for generation of cancer vaccines that can be customized to the specific tumor DNA sequence for a patient. Such developments are anticipated to fuel the scientific interest in utility of the technique for vaccine development. Thus, the rising prospects for DNA vaccines that use engineered DNA to induce an immunogenic response against viruses, parasites, cancer, and bacteria are anticipated to drive the segment.

End Use Insights

The biopharmaceutical companies segment held the largest market share of 48.21% in 2024. This is attributed to the growing investments in research & development, which have fueled the demand for advanced enzymatic DNA synthesis technologies. These investments reflect the growing need for innovative solutions in drug discovery and development, further solidifying the segment's leading position in the market. Thus, propelling the growth of the segment over the forecast period.

The contract research organizations segment is expected to witness a fastest CAGR over the forecast period due to the increasing demand for outsourced research and development services from biotechnology and pharmaceutical companies. In addition, the growing complexity of clinical trials and the need for advanced genetic analysis and diagnostics are further boosting the demand for enzymatic DNA synthesis services provided by CROs.

Regional Insights

North America dominated the market and accounted for a 49.83% share in 2024 owing to the growing research infrastructure, high levels of investment in biotechnology, and significant presence of key market players. Moreover, the strong emphasis on innovation and development in genetic research, coupled with substantial funding from both government and private sectors, has propelled the growth of the market over the forecast period.

U.S. Enzymatic DNA Synthesis Market Trends

The enzymatic DNA synthesis market in the U.S. is expected to grow over the forecast period due growing funding to advance enzymatic DNA synthesis technologies. For instance, in April 2021, the U.S. government invested around USD 1.7 billion in Association of American Medical Colleges genome sequencing to better detect, monitor, and mitigate COVID-19 variants.

Europe Enzymatic DNA Synthesis Market Trends

Europe enzymatic DNA synthesis market was identified as a lucrative region in this industry. Strong research & development in biology, pharmaceuticals, & therapeutics, established research institutions and a growing number of biotech startups, and the increasing demand for advanced genetic testing in the region are factors driving market growth.

The enzymatic DNA synthesis market in the UK is expected to grow over the forecast period. The ongoing advancement in biomedical research is anticipated to propel the demand for enzymatic DNA synthesis market.

France enzymatic DNA synthesis marketis anticipated to grow over the forecast period. This is driven by increasing investments in synthetic biology and precision medicine. Government support for biotech innovation and sustainable alternatives to chemical synthesis is further accelerating adoption. Additionally, rising demand for high-fidelity, long-strand DNA is fueling market expansion.

Asia Pacific Enzymatic DNA Synthesis Market Trends

Asia Pacific enzymatic DNA synthesis market is anticipated to witness the fastest CAGR of 27.47% from 2025 to 2033 in the enzymatic DNA services market. Rapid advancements in biotechnology, expansion of healthcare infrastructure, rising investments in genomics and personalized medicine, and increasing research activities across the region are contributing to the growth of the market over the forecast period.

The enzymatic DNA synthesis market in China is expected to grow over the forecast period. The rise of CROs and the outsourcing of drug discovery & development activities by pharmaceutical & biotech companies is anticipated to drive the growth of enzymatic DNA synthesis market.

Japan enzymatic DNA synthesis market is anticipated to grow at a significant CAGR over the forecast period. The growing adoption of precision medicine and personalized healthcare in Japan is boosting the demand for DNA sequencing, and gene editing diagnostic application, thereby, expected to propel market growth.

The enzymatic DNA synthesis market in India is anticipated to grow at a rapid rate over the forecast. This is attributed to the active promoting by the Indian government in the development of biotechnology and healthcare infrastructure.

Middle East and Africa Enzymatic DNA Synthesis Market Trends

The enzymatic DNA synthesis market in Middle East and Africa is projected to grow in near future due to the increasing investment in healthcare and biotechnology infrastructure and the growing focus on genomics and the expansion of research institutions across the region.

The enzymatic DNA synthesis market in Saudi Arabia is expected to grow over the forecast period due to the growing invests in biotechnology and life sciences initiatives, including R&D initiatives is expected to drive the demand for enzymatic DNA synthesis in various applications, such as genomics, diagnostics, and therapeutics.

Key Enzymatic DNA Synthesis Company Insights

The enzymatic DNA synthesis (EDS) market is characterized by a blend of established synthetic biology firms and emerging innovators. Telesis Bio Inc. has remained a frontrunner with its BioXp systems that automate and accelerate the synthesis of genes using enzymatic methods. Twist Bioscience Corporation, while traditionally dominant in chemical synthesis, is expanding its portfolio to support hybrid platforms, blending enzymatic capabilities with its high-throughput infrastructure. GenScript Biotech Corp., a key player in gene synthesis services, is gradually integrating enzymatic synthesis technologies to meet rising demand for accuracy and speed in custom gene assembly. These firms collectively hold a sizable share of the commercial DNA synthesis landscape and continue to invest in R&D for improved enzyme efficiency and scalability.

Several early-stage and innovation-driven companies are reshaping the competitive dynamics. Evonetix and Ansa Biotechnologies, Inc. are focusing on novel chip-based and sequence-perfect enzymatic synthesis, respectively, offering capabilities to synthesize long, complex DNA fragments. Camena Bio is gaining traction through its proprietary DNA assembly platforms aimed at synthetic biology applications. Molecular Assemblies stands out for its Fully Enzymatic Synthesis technology, developed in collaboration with Codexis, which enables the synthesis of long and accurate DNA strands for therapeutics and diagnostics. DNA Script, based in France, is another major contributor, pioneering benchtop enzymatic DNA printers that support decentralized and on-demand gene synthesis, particularly for academic and pharmaceutical labs.

Meanwhile, Touchlight and Kern Systems are leveraging proprietary enzymatic processes to produce DNA for advanced therapeutics and data storage solutions. Touchlight's "doggybone" DNA format and Kern Systems’ high-fidelity synthesis platforms are enabling use cases beyond traditional gene synthesis, including vaccine production and biocomputing. As these firms continue to forge academic, industrial, and government collaborations, the competitive landscape is expected to evolve rapidly. Strategic initiatives such as licensing, joint ventures, and early access programs are helping companies expand market penetration and commercial readiness. Overall, the EDS market remains moderately consolidated, with innovation-driven differentiation defining market share leadership.

Recent Developments

• In February 2025, Scientists in Paris are advancing enzymatic DNA synthesis technology to streamline mRNA vaccine production. With USD 4.7 million in CEPI funding, DNA Script aims to automate synthetic DNA template manufacturing, accelerating vaccine timelines and expanding global accessibility especially in the Global South.

• In May 2025, Telesis Bio has licensed its Gibson SOLA enzymatic synthesis platform to Regeneron, enabling high-throughput, on-demand gene synthesis directly within Regeneron’s R&D labs. This strategic move supports faster biologics discovery by reducing DNA and mRNA production timelines from weeks to hours, highlighting the growing adoption of enzymatic DNA synthesis for agile, in-house workflows.

• In May 2025, Ansa Biotechnologies has launched a 50 kb DNA synthesis early access program, offering ultra-long, complex DNA sequences in under four weeks. This milestone showcases the scalability of enzymatic DNA synthesis for advanced applications in genomics, agriculture, and cell and gene therapy-further positioning Ansa as a leader in long-fragment synthetic DNA.

Enzymatic DNA Synthesis Market Report Scope

Global Enzymatic DNA Synthesis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global enzymatic DNA synthesis market report based on services, application, end use, and region. 

• Services Outlook (Revenue, USD Million, 2021 - 2033)

  • Oligonucleotide Synthesis

  • Gene Synthesis

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Synthetic Biology

  • Genetic Engineering

  • Vaccine Development

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Biopharmaceutical Companies

  • Academic & Research Institutes

  • Contract Research Organizations

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Chile

  • MEA

    • Saudi Arabia

    • UAE

    • Kuwait